Epitope Diagnostics Inc. joins MetroConnect to expand international growth


SAN DIEGO – Epitope Diagnostics pleased to announce it has been selected to take part in MetroConnect 2018, an export assistance program run by the World Trade Center San Diego (WTC) and designed to help San Diego companies accelerate their global growth.

This program will allow Epitope Diagnostics to have further spending on R&D in order to stay competitive in the IVD market by manufacturing niche products that call for extremely expensive reagents for development.  This program will also help Epitope’s exhibition costs that will in turn benefit healthcare in regions and territories where our products are not established.

 “With this opportunity, an increase in exports will allow Epitope to promote the San Diego community while fostering business and exportation partnerships.” – Stefanie Dallozette – Business Operations Manager

As the flagship export assistance program of World Trade Center San Diego, MetroConnect helps to cultivate a pipeline of export-ready firms to elevate San Diego’s global reach. Now in its fourth program-year, company participants will receive a $10,000 grant, presented by JPMorgan Chase & Co., and a suite of programmatic support services to assist with international expansion strategies. Local companies,  Epitope Diagnostics included, will have access to a dedicated staff manager at WTC, and will receive guidance on export compliance, financing and fundraising, among other international support services.

 “We applaud Epitope Diagnostics Inc. for taking the next step in going global,” said Nikia Clarke, executive director of World Trade Center San Diego. “With SMEs like this at the forefront, San Diego must continue to increase its export capacity and boost the region’s global identity. MetroConnect is equipping these companies with the resources necessary to do just that.”

The MetroConnect program is highly competitive, with just 20 companies selected based on a variety of criteria including market interest, assessed impact of funds, current international traction and more. Applicants were assessed by a panel of judges, including representatives from Qualcomm Ventures, Biocom, U.S. Commercial Service, Rough Draft Brewing, San Diego State University,  UC San Diego, San Diego Regional EDC and WTC San Diego.

Epitope Diagnostics Inc. joins a cohort of 19 other companies representing a unique cross-section of San Diego’s industries, from defense to life sciences to software and craft goods – each with plans to take San Diego innovation globally. Collectively, the cohort employs 1,181 and has a combined revenue of $392 million revenue and $115 million in international revenue.

Participating companies will also be considered for the program’s MetroConnect Grand Prize Pitchfest in June 2019, which will provide an additional $35,000 to help one or two companies further advance their global agendas. Past grand prize winners include Cypher Genomics (now part of Human Longevity, Inc.), Rough Draft Brewing and CureMatch.

MetroConnect is underwritten by JPMorgan Chase & Co., with additional support provided by Air Canada, Japan Airlines, Japan External Trade Organization, Qualcomm, SYSTRAN, Taylor Guitars, Lufthansa, City of San Diego and others.

The announcement was made by Mayor Kevin L. Faulconer and WTC San Diego on September 26 at WeWork.

New Anti-Müllerian Hormone ELISA Kit Launched

Anti-Müllerian hormone (AMH) is uniquely produced by granulosa cells of ovarian follicles during folliculogenesis. It is currently the best measure of ovarian reserve in the clinical setting and may also be used to predict ovarian response in IVF and to monitor patients with a history of granulosa cell tumors.


Epitope Diagnostics is proud to present a robust AMH ELISA kit with the following specifications:


This kit is currently available for research use in the United States (KTR-804) and for IVD use (KT-804) internationally.

Epitope Diagnostics Launches a Novel 25-OH Vitamin D ELISA Kit

San Diego, CA, May 11, 2015 --( According to data from the National Health and Nutrition Examination Survey, from 2001 to 2006, about one quarter of the U.S. population had inadequate levels of vitamin D and about 8% were at risk for vitamin D insufficiency.

Epitope Diagnostics, Inc. has launched a novel CE marked ELISA kit to measure total 25-Hydroxy Vitamin D2 and D3.

Vitamin D is a compound that is essential to the human body. Insufficiency and deficiency increases the risk of bone fractures and debilitating bone related disease, such as osteoporosis.

Vitamin D comes in many forms such as D2 (ergocalciferol) and D3 (cholecaliferol). Their hydroxylated forms, 25-OH vitamin D2 and 25-OH vitamin D3 (calcifidiol) are the biologically active forms. The function of these molecules to help regulate the uptake of calcium in the gut in order to maintain a healthy skeletal system.

Insufficient vitamin D levels correspond to low levels of calcium and increase bone related health risks. An overdose of vitamin D, which may come from taking too many supplements, can lead to vitamin D toxicity and even death. The importance of measuring this molecule cannot be overstated.

Epitope Diagnostics’ Total 25-OH Vitamin D ELISA kit is a robust 2-hour assay that reliably measures both forms of active vitamin D in serum or EDTA-plasma samples.

In current vitamin D assays, blood samples must be prepared and processed to release vitamin from its bound form before it can be measured with an assay. The Epitope Diagnostics Total 25-OH Vitamin D ELISA kit is unique in that a special buffer has been included to separate vitamin D from its binding protein in the assay well so no extra sample processing steps are required.

In addition, this kit has been streamlined to be user friendly and time efficient. It features a set of liquid standards and controls, ready-to-use liquid tracer, and liquid biotinylated vitamin D analog. It has a high analytical sensitivity of 0.96 ng/ml with the highest calibrator being 150 ng/ml.

“Vitamin D deficiency is a serious problem, especially now when so many people in our community don’t get enough of it. On the other hand, it’s easy to get supplements at variable doses over the counter these days so vitamin D overdose is also a concern,” said Ping Gao, President and CEO. “We’re proud to present this kit as part of the solution.”

Website Relaunch

Our new website has arrived!

This was a major update from our old site, which was beginning to deteriorate without a dedicated webmaster so we're happy to have a brand new, up-to-date version 2.0 release. Currently, the only the product list is available for viewing, but we are slowly rolling out individual product pages over the next few weeks. Please be patient, as many improvements are happening behind the scenes.

As always, if you see any broken links, or have any questions, please let us know through the contact page.


EDI launches new anti-auristatin monoclonal antibodies and ELISA kits

Epitope Diagnostics is proud to announce that a new set of monoclonal antibodies specific to auristatins is now commercially available. The novel clones are specific against detecting monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF), two anti-cancer compounds. Using these new monoclonal antibodies, we were able to successfully develop highly sensitive MMAE-ADC and MMAF-ADC ELISA kits.

Read More